Natalizumab (Tysabri, Biogen Idec/ Elan), a once-monthly IV drug for multiple sclerosis, will be available again under a restricted distribution program. It was pulled from the market last year because of a life-threatening side effect.
Approved in November 2004, the drug was voluntarily withdrawn in February 2005 after two patients in clinical trials died of progressive multifocal leuko-encephalopathy, a rare brain infection. canadian pharmacy generic viagra
This drug is to be used alone in patients who have not responded adequately to, or who cannot tolerate, other MS drugs.